MX2021009055A - Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. - Google Patents
Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo.Info
- Publication number
- MX2021009055A MX2021009055A MX2021009055A MX2021009055A MX2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A MX 2021009055 A MX2021009055 A MX 2021009055A
- Authority
- MX
- Mexico
- Prior art keywords
- arterial hypertension
- pulmonary arterial
- treating pulmonary
- ethyl
- rodatristat
- Prior art date
Links
- 206010064911 Pulmonary arterial hypertension Diseases 0.000 title abstract 3
- TZSZZENYCISATO-WIOPSUGQSA-N rodatristat Chemical group CCOC(=O)[C@@H]1CC2(CN1)CCN(CC2)c1cc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)nc(N)n1 TZSZZENYCISATO-WIOPSUGQSA-N 0.000 title abstract 2
- DUUGKQCEGZLZNO-UHFFFAOYSA-N 5-hydroxyindoleacetic acid Chemical compound C1=C(O)C=C2C(CC(=O)O)=CNC2=C1 DUUGKQCEGZLZNO-UHFFFAOYSA-N 0.000 abstract 2
- 239000002552 dosage form Substances 0.000 abstract 2
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- ZNSPHKJFQDEABI-NZQKXSOJSA-N Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 Chemical compound Nc1nc(O[C@H](c2ccc(Cl)cc2-c2ccccc2)C(F)(F)F)cc(n1)N1CCC2(CN[C@@H](C2)C(O)=O)CC1 ZNSPHKJFQDEABI-NZQKXSOJSA-N 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 230000002485 urinary effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962798827P | 2019-01-30 | 2019-01-30 | |
| PCT/IB2020/000074 WO2020157577A1 (en) | 2019-01-30 | 2020-01-30 | A dosage regime and method for treating pulmonary arterial hypertension with rodatristat ethyl |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2021009055A true MX2021009055A (es) | 2021-10-22 |
Family
ID=70285725
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2021009055A MX2021009055A (es) | 2019-01-30 | 2020-01-30 | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11607413B2 (https=) |
| EP (1) | EP3917531A1 (https=) |
| JP (1) | JP2022518944A (https=) |
| KR (1) | KR20210133953A (https=) |
| CN (1) | CN113557022A (https=) |
| AU (1) | AU2020213746A1 (https=) |
| CA (1) | CA3128327A1 (https=) |
| MX (1) | MX2021009055A (https=) |
| WO (1) | WO2020157577A1 (https=) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20210102887A (ko) * | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
| JP2022507533A (ja) * | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 |
| US20200188399A1 (en) * | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating interstitial lung disease |
| US11607413B2 (en) | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
| WO2023062595A1 (en) | 2021-10-14 | 2023-04-20 | Altavant Sciences Gmbh | Treatment of subjects having pulmonary arterial hypertension with rodatristat ethyl |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101815534A (zh) | 2007-07-11 | 2010-08-25 | 莱西肯医药有限公司 | 用于治疗肺动脉高压以及相关疾病和病症的方法和组合物 |
| UA119247C2 (uk) | 2013-09-06 | 2019-05-27 | РОЙВЕНТ САЙЕНСИЗ ҐмбГ | Спіроциклічні сполуки як інгібітори триптофангідроксилази |
| KR20210102887A (ko) | 2018-11-14 | 2021-08-20 | 알타반트 사이언시스 게엠베하 | 말초 세로토닌과 관련된 질병 또는 장애를 치료하기 위한 트립토판 하이드록실라제 1 (tph1)의 결정질 스피로사이클릭 화합물 억제제 |
| JP2022507533A (ja) | 2018-11-16 | 2022-01-18 | アルタバント・サイエンシズ・ゲーエムベーハー | 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法 |
| US20200188399A1 (en) | 2018-12-17 | 2020-06-18 | Altavant Sciences Gmbh | Method for treating interstitial lung disease |
| WO2020128608A1 (en) | 2018-12-17 | 2020-06-25 | Altavant Sciences Gmbh | Compound for use in a method for treating sarcoidosis-associated pulmonary hypertension |
| US11607413B2 (en) | 2019-01-30 | 2023-03-21 | Altavant Sciences Gmbh | Dosage regime and method for treating pulmonary arterial hypertension |
| US11576915B2 (en) * | 2019-03-15 | 2023-02-14 | Altavant Sciences Gmbh | Method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension and daily dosing |
-
2020
- 2020-01-30 US US16/777,458 patent/US11607413B2/en active Active
- 2020-01-30 JP JP2021544351A patent/JP2022518944A/ja active Pending
- 2020-01-30 AU AU2020213746A patent/AU2020213746A1/en not_active Abandoned
- 2020-01-30 CN CN202080016400.5A patent/CN113557022A/zh active Pending
- 2020-01-30 CA CA3128327A patent/CA3128327A1/en active Pending
- 2020-01-30 EP EP20718760.0A patent/EP3917531A1/en not_active Withdrawn
- 2020-01-30 MX MX2021009055A patent/MX2021009055A/es unknown
- 2020-01-30 KR KR1020217024232A patent/KR20210133953A/ko not_active Abandoned
- 2020-01-30 WO PCT/IB2020/000074 patent/WO2020157577A1/en not_active Ceased
-
2023
- 2023-01-25 US US18/159,494 patent/US20240041877A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US11607413B2 (en) | 2023-03-21 |
| JP2022518944A (ja) | 2022-03-17 |
| CN113557022A (zh) | 2021-10-26 |
| CA3128327A1 (en) | 2020-08-06 |
| US20200237759A1 (en) | 2020-07-30 |
| AU2020213746A1 (en) | 2021-08-19 |
| WO2020157577A8 (en) | 2020-10-15 |
| WO2020157577A1 (en) | 2020-08-06 |
| EP3917531A1 (en) | 2021-12-08 |
| US20240041877A1 (en) | 2024-02-08 |
| KR20210133953A (ko) | 2021-11-08 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2021009055A (es) | Pauta posológica y método para tratar la hipertensión arterial pulmonar con rodatristat etilo. | |
| US8278300B2 (en) | Use for PDE5 inhibitors | |
| EA029407B1 (ru) | Композиции и способы уменьшения содержания алкоголя в крови | |
| MX2021011224A (es) | Un método para tratar la hipertensión arterial pulmonar y la hipertensión arterial pulmonar asociada y pauta posológica diaria. | |
| WO2008054695A2 (en) | Composition and method for etiological treatment and prevention of diseases and/or complications associated with chronic glucose metabolism destabilization | |
| WO1998037883A1 (en) | Forskohlin for promoting lean body mass | |
| US20170042928A1 (en) | Edible Energy Composition | |
| WO2014043025A1 (en) | Multiple folate formulation and use thereof | |
| CA3119909A1 (en) | A method for treating pulmonary arterial hypertension and associated pulmonary arterial hypertension | |
| US12194042B2 (en) | Uses | |
| US12226374B2 (en) | Compositions comprising quinone and/or quinol and methods of preparations and use thereof | |
| Singh et al. | Alcohol drinking in rats is attenuated by the mixed 5-HT1 agonist/5-HT2 antagonist FG 5893 | |
| US5217974A (en) | Method for treating gar-transformylase tumors in mammals and reducing mammalian toxicity | |
| JP4604515B2 (ja) | 眼科用剤 | |
| CN1705476A (zh) | 酒精代谢的增强 | |
| CN110101849B (zh) | 一种酶催化解酒作用的组合物及其制备方法与应用 | |
| Kovach et al. | Contribution of adenosine to the regulation of cerebral blood flow: the role of calcium ions in the adenosine-induced cerebrocortical vasodilatation | |
| US20210121469A1 (en) | Edible Energy Composition | |
| KR101841553B1 (ko) | 오르니친 또는 오르니친 염을 포함하는 성기능 개선용 조성물 | |
| EP0505640B1 (en) | Improved therapeutic method | |
| Sasaki et al. | Stimulatory effect of Coca-ColaTM on gastroduodenal HCO3− secretion in rats | |
| WO2020168396A1 (en) | Food supplement to improve the heart function | |
| EP3927187A1 (en) | Food supplement to improve the heart function | |
| Unger25 et al. | Third Congress of the Hungarian Pharmacological Society, Budapest | |
| WO1993010788A1 (en) | Methods and compositions for treating sleep disorders, convulsive seizures, and other disorders using optically pure (-) zopiclone |